Cogent Biosciences Reports Recent Business Highlights and Fourth Quarter and Full Year 2024 Financial Results

• Top-line results from SUMMIT trial in NonAdvSM patients expected July 2025 • APEX trial enrollment in AdvSM patients complete; top-line results expected in 2H 2025 • Top-line results from PEAK trial in 2nd-line GIST patients expected by end of 2025 • $312 million sufficient to fund operations well past clinical readouts, into late 2026; includes gross proceeds from ATM sale in February 2025 WALTHAM, Mass. and BOULDER, Colo., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biot ...